Open Nav

Infinity Pharmaceuticals, Inc.

  • Jayne Kauffman, Infinity Pharmaceuticals

Communicate IPI-549 and Infinity investment thesis to broader investor audience.

  • Date:Wednesday, October 17
  • Time:11:15 AM - 11:30 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:We are an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. We are focusing our efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
  • Company
  • Company HQ City:Cambridge
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • Ticker:INFI
  • Exchange:Nasdaq
  • CEO/Top Company Official:Adelene Q. Perkins
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :IPI-549
  • Development Phase of Primary Product:Phase I
Jayne Kauffman
Infinity Pharmaceuticals